Posted by Michael Wonder on 08 May 2018
Two years of PRIME
7 May 2018 - Driving innovation to where it is most needed.
In the two years since its launch, the PRIority Medicines scheme (PRIME) of the EMA has succeeded in driving innovation and improved the efficiency of the development process in therapeutic areas with the most pressing unmet medical needs. The goal is to support and optimise medicine development, so that patients whose diseases cannot be treated or who need better treatment options have access to new medicines that enable them to live healthier lives.
The report, published today, presents results from the first two years of PRIME. It explains how the criteria for eligibility to the scheme have been applied and what type of support applicants have received so far.
